Skip to main content

Advertisement

Table 2 Patient, treatment and laboratory characteristics of patients with androgen deficiency and patients with normal androgen levels

From: Androgen deficiency in male patients diagnosed with ANCA-associated vasculitis: a cause of fatigue and reduced health-related quality of life?

Characteristics Normal androgen levels (number = 37) Androgen deficiency (number = 33) P
Age at study (years), mean (SD) 55 (13) 64 (10) 0.005
Diagnosis to study (months), median (IQR) 75 (39 to 119) 129 (70 to 168) 0.041
Last relapse to study (months), median (IQR) 36 (19 to 67) 49 (19 to 73) 0.403
BVAS = 0, n 37 33  
VDI, median (IQR) 3 (2 to 4) 4 (2 to 5) 0.045
Cum. CY (g.), median (IQR) 22.4 (15.5 to 39.8) 46.6 (18.0 to 92.0) 0.049
Cum. GC (g.), median (IQR) 10.6 (6.1 to 18.4) 21.7 (13.5 to 33.0) 0.001
TT (nmol/L), mean (SD) 17.4 (5.5) 9.8 (1.9) <0.001
FT (pmol/L), mean (SD) 313 (103) 193 (51) <0.001
SHBG (nmol/L), mean (SD) 43 (12) 35 (15) 0.029
Hb (mmol/L), mean (SD) 9.0 (1.0) 8.4 (0.9) 0.009
CRP (mg/L), median (IQR) <5 (<5 to <5) <5 (<5 to 9) 0.072
CC (ml/min), mean (SD) 91 (27) 89 (39) 0.811
Treatment at study    
No treatment, number 11 7  
CT, number 9 5  
GC (+ CT), number 3 (1) 7 (2)  
Aza (+CT), number 8 (6) 2 (1)  
MMF (+CT), number 3 (3) 2 (1)  
GC and Aza (+CT), number 1 (1) 6 (6)  
GC and MMF (+CT), number 2 (2) 4 (3)  
  1. Aza, azathioprine; BVAS, Birmingham Vasculitis Activity Score; CC, creatinine clearance; CRP, C-reactive protein; CT, co-trimoxazole, 2 dd 800/160 mg; Cum. CY, cumulative cyclophosphamide; Cum. GC, cumulative glucocorticoid; FT, free testosterone; Hb, hemoglobin; MMF, mycophenolate mofetil; SHBG, sex hormone-binding globulin; TT, total testosterone; VDI, Vasculitis Damage Index.